Shares of Sellas Life Sciences Group Inc. (Nasdaq:SLS) jumped 151 percent to close at $8.65 on Monday after the company said an interim analysis of an exploratory phase IIb study seeking the right patient population for its cancer immunotherapy, Neuvax (nelipepimut-S), showed it working synergistically with Herceptin (trastuzumab, Roche Holding AG), making a "clinically meaningful difference" in median disease-free survival for women with triple-negative breast cancer (TNBC).